PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCisplatin
Cisplatin
Cisplatin (cisplatin) is a small molecule pharmaceutical. Cisplatin was first approved as Cisplatin on 1982-01-01. It is used to treat amelanotic melanoma, astrocytoma, breast neoplasms, cystic mesothelioma, and esophageal neoplasms amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
Cisplatin (discontinued: Cisplatin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cisplatin
Tradename
Company
Number
Date
Products
CISPLATINHQ Specialty PharmaN-018057 RX1982-01-01
2 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cisplatinANDA2024-12-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
prostatic neoplasms—D011471C61
breast neoplasmsEFO_0003869D001943C50
ovarian neoplasmsEFO_0003893D010051C56
stomach neoplasmsEFO_0003897D013274C16
esophageal neoplasms—D004938C15
non-hodgkin lymphoma—D008228C85.9
lung neoplasms—D008175C34.90
multiple myeloma—D009101C90.0
neuroblastomaEFO_0000621D009447—
urinary bladder neoplasms—D001749C67
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XA: Platinum compounds, antineoplastic drugs
— L01XA01: Cisplatin
HCPCS
Code
Description
J9060
Injection, cisplatin, powder or solution, 10 mg
Clinical
Clinical Trials
4842 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Biliary tract neoplasmsD001661—C24.9——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCisplatin
INNcisplatin
Description
Cisplatin is a chemotherapy medication used to treat a number of cancers. These include testicular cancer, ovarian cancer, cervical cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. It is given by injection into a vein.
Classification
Small molecule
Drug classantineoplastics (platinum derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID15663-27-1
RxCUI—
ChEMBL IDCHEMBL11359
ChEBI ID—
PubChem CID5702198
DrugBankDB00515
UNII IDQ20Q21Q62J (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 141,505 documents
View more details
Safety
Black-box Warning
Black-box warning for: Cisplatin
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
71,356 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use